stockportfolio.pro
Trevi Therapeutics, Inc. (TRVI)
Healthcare · Biotechnology · NasdaqGM
Trevi Therapeutics, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-20.55M | $-26.05M | $-32.76M | $-33.94M | $-29.15M | $-29.07M | $-47.91M | $-42.76M |
| Net margin | — | — | — | — | — | — | — | — |
Source: Trevi Therapeutics, Inc. SEC filings (10-K).
Explore 8 years of Trevi Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TRVI in your portfolio →
Trevi Therapeutics, Inc. financial history by metric
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics, Inc. — frequently asked questions
What is Trevi Therapeutics, Inc.'s revenue?
Trevi Therapeutics, Inc. (TRVI) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Trevi Therapeutics, Inc. profitable?
No — TRVI reported a net loss of $-42.76M in fiscal 2025.
What is TRVI's P/E ratio?
Trevi Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Trevi Therapeutics, Inc. have?
As of fiscal year 2025, TRVI carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Trevi Therapeutics, Inc.'s market cap?
Trevi Therapeutics, Inc. (TRVI) has a market capitalization of about $1.96B, based on the latest data in our nightly-refreshed cache.
When does Trevi Therapeutics, Inc.'s fiscal year end?
TRVI's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Trevi Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.